



European College of
Neuropsychopharmacology

Annual Report 2021



European College of Neuropsychopharmacology

Annual Report 2021

1. About ECNP	3
2. Activities 2021	5
3. Financial Overview	7
Financial statements	7
4. Future Outlook	9



The European College of Neuropsychopharmacology is a public-interest-serving entity (*algemeen nut beogende instelling* – ANBI) under Dutch tax law.

1. About ECNP

ECNP is an independent European scientific association that exists to promote high-quality experimental and clinical research in applied and translational neuroscience with a view to stimulating the development of better treatments for those suffering from disorders of the brain.

The mission of ECNP is to advance the science of the brain, promote better treatment and enhance brain health. It is non-profit-making.

Address: Daltonlaan 400, 3584 BK Utrecht

E-mail: secretariat@ecnp.eu

Website: <https://www.ecnp.eu>

RSIN: 823523974

Dutch TAX number: NL 823523974B01

ANBI: The European College of Neuropsychopharmacology is a public-interest-serving entity (*algemeen nut beogende instelling* – ANBI) under Dutch tax law.

The European College of Neuropsychopharmacology is referred to hereafter as 'ECNP' or 'the College'.

Executive Committee

Officers

Gitte Moos Knudsen
President

Copenhagen University Hospital
Denmark

Elisabeth Binder
Vice-President

Max Planck Institute of Psychiatry
Munich, Germany

Celso Arango
Past-President

Hospital General Universitario Gregorio Marañón
Madrid, Spain

Martien Kas
President-Elect

University of Groningen,
The Netherlands

Catherine Harmer
Treasurer

University of Oxford,
United Kingdom

Suzanne Dickson
Secretary

University of Göteborg,
Sweden

Councillors

David Baldwin

University of Southampton
United Kingdom

Damiaan Denys	Academic Medical Center Amsterdam The Netherlands
Marion Leboyer	Hôpital Albert Chenevier Creteil, France
Brenda Penninx	Amsterdam University Medical Center The Netherlands
Andreas Reif	University Hospital Frankfurt – Goethe University Germany
Gil Zalsman	Geha Mental Health Center, Tel Aviv University Petah Tikva, Israel

Co-opt member

Gerry-Dawson	Chief Scientific Officer, P1 vital Wallingford, United Kingdom
---------------------	---

Ex officio members

Andreas Meyer-Lindenberg	Editor-in-Chief, <i>European Neuropsychopharmacology</i> Central Institute of Mental Health (ZI) Mannheim, Germany
Andreas Reif	Chair, Scientific Programme Committee – 32 nd , 33 rd , 34 th ECNP Congress University Hospital Frankfurt – Goethe University Germany

Executive Director

Alexander Schubert	Utrecht, The Netherlands
---------------------------	--------------------------

The members of the Executive Committee receive no remuneration for their role. The President receives € 15,000 per annum, payable to her institution, for secretarial assistance. Each Officer receives € 4,000 per annum, payable to his or her institution, for secretarial assistance. And each member of the Executive Committee is entitled to € 1,500 per annum to cover associated meeting costs, including ground transportation, lunch, dinner, drinks, etc.

2. Activities 2021

To execute its mission to support European applied and translational neuroscience, ECNP performs a number of activities annually, focusing especially on stimulating research, sponsoring education and raising awareness.

Promoting and disseminating science

European Neuropsychopharmacology

ECNP publishes, in partnership with Elsevier B.V., the international peer-reviewed journal *European Neuropsychopharmacology*, featuring the latest in applied brain science across the spectrum of basic and clinical and research. The 2021 impact factor is 4.600.

Special issues included:

- Abstracts of the ECNP Workshop for Early Career Scientists in Europe Virtual 2021. 44 suppl. 1, March 2021.
- Opportunities and Challenges in Drug Development for ASD: Product of ISCTM/ECNP Joint Working Group. 48, July 2021.
- Abstracts of the 34th ECNP Congress Lisbon 2021 Hybrid. 53 suppl. 1, December 2021.

ECNP Networks and Thematic Working Groups (TWGs)

These virtual, multi-centre European research clusters provide a unique platform for the collection and aggregation of continent-wide clinical data, in order to foster research collaboration and ideas-sharing across the translational neurosciences.

The 17 Networks and four Thematic Groups collectively comprise one of ECNP's most far-reaching initiatives, bringing together several hundred of Europe's leading researchers in applied and translational neuroscience, and providing the springboard for some of the region's largest and most important projects in brain research.

The International Society for CNS Clinical Trials and Methodology (ISCTM)

ISCTM is an independent organisation devoted to advancing clinical research methods related to the development and use of central nervous system (CNS) therapeutics. Every two years the ECNP-ISCTM joint meeting brings together international stakeholders in academia, industry, government, and the regulatory and payer communities to address strategic clinical, regulatory, methodological and policy challenges in CNS clinical research.

The 2021 joint meeting was held on 1-2 October in Lisbon, Portugal.

ECNP Neuropsychopharmacology Award

This award, conferred annually, recognises exceptional research achievements in applied and translational neuroscience, alternating between basic and clinical science. The award comes with an unrestricted prize of € 10,000.

Winner 2021: Valery Grinevich, Germany (preclinical)

Fostering talent

ECNP Rising Star Award

The ECNP Rising Star Award honours early career researchers in applied and translational neuroscience who have the potential to advance the science of treatment and prevention of brain disorders. Conferred for the first time in 2020, in 2021 the number of awards was doubled. The award comes with an unrestricted prize of € 2,000 for each winner.

Winners 2021: Covadonga M. Díaz-Caneja, Spain
Dominique Endres, Germany

Public outreach

ECNP Co-morbidity Study

Funded by ECNP, this major study in collaboration with the London School of Economics (LSE) and Medical University of Vienna (MUV) aims to provide a large-scale quantitative analysis of the frequency with which disorders of the brain coincide with somatic illnesses, and how this challenge is to be managed from a public health perspective. The first study of this scale and complexity ever attempted, it is due to be published in late 2022.

European Affairs

ECNP collaborates with a number of European societies to build European research and clinical capacity and advance the interests of the neuroscience research and best-practices treatment in Europe.

- Biomedical Alliance in Europe – member
- European Brain Council (EBC) – founding member
- European Federation of Psychiatric Trainees (EFPT) – supporter
- Federation of European Neuroscience Societies (FENS) – founding member
- Expert Platform on Mental Health – Depression (EPD) – supporter
- Global Alliance of Mental Illness Advocacy Networks (GAMIAN-Europe) – member

3. Financial Overview

ECNP's policy is at all times to handle its disposable assets in a responsible and sustainable manner. The principles of this policy are:

- Proactive tax and regulatory compliance
- Capital preservation – and adherence to agreed levels
- Budgetary discipline
- Ongoing diversification of the revenue base

To give substance to this, ECNP invests in securities through an established asset manager using a defensive policy. The goal is to preserve wealth, to ensure the College can continue to perform its public-good activities, not to maximise return.

Financial statements

Balance sheet as at 31 December 2021 (after appropriation of profit/losses)

	31-12-2021		31-12-2020	
	€	€	€	€
ASSETS				
FIXED ASSETS				
Financial fixed assets				
Securities		15,812,970		16,261,286
CURRENT ASSETS				
Accounts receivable				
Amounts owed by other foundations		-		197,522
Taxes		797		1,436
Other accounts receivable		141,166		113,624
		141,963		312,582
Bank deposits		511,255		376,562
		653,218		689,144
		16,466,188		16,950,430

	31-12-2021		31-12-2020	
	€	€	€	€
EQUITY AND LIABILITIES				
EQUITY				
Other reserves		16,355,526		16,696,896
CURRENT LIABILITIES				
Trade creditors	29,832		200,304	
Other liabilities	80,830		53,230	
		110,662		253,534
		<u>16,466,188</u>		<u>16,950,430</u>

Statement of income and expenditure 2021

	Balance 2021	Balance 2020
	€	€
Income		
Membership fees	78,549	87,286
Donation	-	1,000,000
Royalties	122,203	108,586
Interest and similar income	51,684	1,180,396
Total income	<u>252,436</u>	<u>2,376,268</u>
Expenses		
Administration	268,529	285,729
Other expenses	125,650	100,549
European Neuropsychopharmacology	32,617	34,984
Other activities	163,130	201,767
Interest and similar charges	3,880	22,002
Total expenses	<u>593,806</u>	<u>645,031</u>
Net result	<u>-341,370</u>	<u>1,731,237</u>
Appropriation of result		
Other reserves	<u>-341,370</u>	<u>1,731,237</u>

4. Future Outlook

In 2021 ECNP, in conjunction with the ECNP Research and Scholarship Foundation launched a broad-scale reassessment of the College's impact in the community it serves and the translational neuroscience field more generally. Two initiatives were established to drive this reassessment:

The *Innovation Task Force* to explore how ECNP's programmes and activities should be adapted to accommodate the new ways science is increasingly being exchanged, communicated, taught and published, and how ECNP programmes and activities can be scaled to respond to the full breadth of the need they are designed to serve.

The *Sustainability Task Force* to explore how ECNP's environmental footprint can be resized to meet sustainability targets.

It is expected that, as the College transitions to new online and hybrid formats, a parallel process of renovating ECNP's governance, management and operational practices will be conducted.